What is the pathophysiology underlying the adverse effects of zidovudine?

Pathophysiology of Zidovudine Side Effects

Zidovudine's adverse effects stem primarily from mitochondrial toxicity caused by inhibition of mitochondrial DNA polymerase gamma, leading to mitochondrial DNA depletion and dysfunction across multiple organ systems. 1

Primary Mechanism: Mitochondrial Toxicity

The fundamental pathophysiologic mechanism underlying zidovudine toxicity is the inhibition of DNA polymerase gamma, the enzyme responsible for mitochondrial DNA (mtDNA) replication. 2 This inhibition occurs because zidovudine, as a nucleoside analogue, is incorporated into the growing DNA chain and causes chain termination. 2

Mitochondrial DNA Depletion

• Zidovudine causes quantitative depletion of mtDNA, reducing the number of mitochondrial DNA copies within cells. 3, 4
• The drug also induces qualitative mtDNA abnormalities, including the "common deletion" mutation that appears at high frequencies in treated patients. 3
• These mtDNA alterations impair expression of mtDNA-encoded respiratory chain components, disrupting cellular energy production. 3

Tissue-Specific Manifestations

The mitochondrial toxicity manifests differently across organ systems:

Hematologic Toxicity (Bone Marrow)

• Anemia and neutropenia result from bone marrow suppression due to mitochondrial dysfunction in rapidly dividing hematopoietic cells. 1, 5
• The frequency and severity are greater in patients with more advanced HIV disease who initiate therapy later in their infection course. 5
• Bone marrow toxicity can progress to aplastic anemia, hemolytic anemia, and pancytopenia with marrow hypoplasia in severe cases. 5

Myopathy

• Skeletal muscle mitochondrial dysfunction causes progressive muscle weakness, wasting, myalgia, and fatigue. 1, 2, 4
• Electron microscopy reveals proliferation of abnormal mitochondria with paracrystalline inclusions, enlarged mitochondria with disrupted cristae architecture, and accumulation of lipid, glycogen, and lipofuscin. 4, 6
• Early myopathy presents with fatigue and exercise intolerance even when muscle strength remains normal, representing subclinical energy shortage within muscle fibers. 4
• Myopathy occurs when a critical threshold of molecular, histological, and biochemical mitochondrial dysfunction is crossed, which varies between individuals. 4

Hepatic Toxicity

• Hepatic mitochondrial dysfunction leads to hepatic steatosis and hepatomegaly. 1, 7
• Liver pathology shows massive macrovacuolar steatosis with ultrastructural mitochondrial abnormalities similar to those in skeletal muscle. 7, 6
• Hepatotoxicity can occur concurrently with myopathy, indicating systemic mitochondrial toxicity. 6

Secondary Mechanisms

Lactic Acidosis

• Impaired mitochondrial oxidative phosphorylation causes cells to rely on anaerobic glycolysis, producing excess lactate. 1
• Symptomatic lactic acidosis with hepatic steatosis represents severe, life-threatening mitochondrial dysfunction. 1
• This syndrome has female preponderance and shares similarities with acute fatty liver of pregnancy and HELLP syndrome, suggesting disorders of mitochondrial fatty acid oxidation. 1
• Fatal cases have been reported, particularly in pregnant women receiving stavudine and didanosine combinations. 1

Oxidative Stress

• Zidovudine induces oxidative stress as a direct mechanism contributing to myotoxicity, independent of mtDNA depletion. 2
• Direct inhibition of mitochondrial bioenergetic machinery occurs, compounding the effects of mtDNA depletion. 2

Lipoatrophy and Fat Redistribution

• Mitochondrial toxicity in adipose tissue causes loss of subcutaneous fat (lipoatrophy). 1, 5
• Paradoxically, zidovudine induces visceral adipose tissue hypertrophy with enlarged adipocytes showing microvesicular steatosis and mitochondrial abnormalities. 3
• VAT adipocytes demonstrate diminished mtDNA copy numbers and impaired respiratory chain protein expression, despite fat accumulation. 3

L-Carnitine Depletion

• Mitochondrial depletion of L-carnitine may contribute to myotoxicity by impairing fatty acid oxidation. 2

Clinical Implications

Common Side Effects

• The most common adverse reactions are headache, malaise, nausea, anorexia, and vomiting in adults. 5
• In pediatric patients, fever, cough, and digestive disorders predominate. 5
• These gastrointestinal effects are predictable and manageable with antimotility and antiemetic agents. 1

Cumulative Toxicity

• Many toxicities are cumulative with prolonged exposure, including peripheral neuropathy, lipoatrophy, and myopathy. 1
• Earlier initiation of zidovudine-based therapy may increase prevalence of these cumulative conditions. 1

Important Caveats

• Serious toxicity is rare when zidovudine is used for short-term postexposure prophylaxis. 1
• The potential for delayed toxicity (oncogenic/teratogenic) remains unknown with long-term exposure. 1
• Zidovudine should be avoided in patients requiring concurrent myelosuppressive agents due to additive hematologic toxicity. 1